Amprion Revenue and Competitors
Estimated Revenue & Valuation
- Amprion's estimated annual revenue is currently $4M per year.
- Amprion's estimated revenue per employee is $155,000
Employee Data
- Amprion has 26 Employees.
- Amprion grew their employee count by 0% last year.
Amprion's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | EVP, Clinical and Regulatory Operations | Reveal Email/Phone |
3 | Director Finance And Operations | Reveal Email/Phone |
4 | Director Research and Development | Reveal Email/Phone |
5 | Chief Commercial Officer | Reveal Email/Phone |
6 | Director Design Controls and Data Analytics | Reveal Email/Phone |
7 | Chief Marketing Officer | Reveal Email/Phone |
8 | Lead Clinical Laboratory Scientist | Reveal Email/Phone |
9 | Senior Research Associate, R&D | Reveal Email/Phone |
10 | Research Associate | Reveal Email/Phone |
Amprion Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Amprion?
Amprion pioneers Prion Early Detection Testing℠for Alzheimer's and Parkinson's. For the first time in history, our proprietary molecular-based diagnostic technology tracks the biomarkers, aka prions including Abeta, Tau and Synuclein, that drive Alzheimer's and Parkinson's prior to any clinical symptoms. Currently awarded FDA Breakthrough Device Designation for the detection of misfolded Synuclein, a biomarker for Parkinson's, the company is also applying the same assay to detect misfolded Abeta and Tau, which are known to cause Alzheimer's. Amprion expects to obtain FDA approvals in the next 18 months and to launch various early detection testing for Alzheimer's and Parkinson's accordingly. Early diagnosis of Alzheimer's and Parkinson's empowers us to find a cure to stop these diseases on their tracks. Learn more about ParkinZheimer—our philosophy and a pillar of our scientific discovery—Alzheimer's and Parkinson's are two related diseases on a spectrum: https://www.amprionme.com/our-philosophy/ Join us in the fight for brain health. Sign up for email alerts on our latest breakthroughs: https://www.amprionme.com/join-the-fight/ == About FDA Breakthrough Device Designation === FDA's Breakthrough Devices Program is designed to speed up development, assessment and review of medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. == How Amprion Works === Amprion's breakthrough early testing for Alzheimer's and Parkinson's tracks the prion biomarkers, using spinal fluid (CSF) and/or blood. Learn more at https://AmprionMe.com. Join the Fight For Brain Health #BrainHealth
keywords:N/A
N/A
Total Funding
26
Number of Employees
$4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Amprion News
Amprion, die Bauherrin der Höchstspannungs-Stromtrasse durch das Heestal, will eine Unterschrift, dass die Amprion GmbH berechtigt ist, zum...
This comes after Amprion submitted the planning approval documents to the Federal Maritime and Hydrographic Agency in March 2021 and the...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.7M | 26 | -21% | N/A |
#2 | $1.8M | 26 | -7% | $24.3M |
#3 | $3.3M | 26 | -26% | $71.2M |
#4 | $1.9M | 26 | -38% | $15.6M |
#5 | $1.7M | 26 | -45% | $34.2M |